Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac174
Abstract: Abstract Pfizer and the Medicines Patent Pool (MPP) have reached a voluntary licensing agreement for Paxlovid (nirmatrelvir+ritonavir), a novel antiviral for coronavirus disease 2019 (COVID-19) taken orally in the first 5 days from symptom onset.… read more here.
Keywords: paxlovid; barriers worldwide; mpp deal; worldwide access ... See more keywords